公开(公告)号：EP0219295A2

公开(公告)日：1987-04-22

申请号：EP86307707.9

申请日：1986-10-06

申请人： NIHON CHEMICAL RESEARCH KABUSHIKI KAISHA also known as JCR PHARMACEUTICALS CO., LTD

发明人： Hiratani, Hajime ,  Tateishi, Jun ,  Kitamoto, Tetsuyuki

IPC分类号： C07K3/26

CPC分类号： C07K14/615 ,  A61K38/00 ,  A61K38/27 ,  A61L2/0017 ,  A61L2/022

摘要： A membrane filter of 0.025 to 0.05 µm pore size is previously treated by passing a solution of a water-soluble high molecular substance such as albumin, dextran,polyvinylpyrrolidone, poly­ethyleneglycol, gelatin or the like through the filter. Employ­ing the filter thus treated, a solution of human growth hormone (HGH) is filtered at high recovery rate of HGH activity to remove Creutzfeldt-Jacob disease pathogen which may exist in HGH pre­parations.

摘要翻译： 预先通过使白蛋白，葡聚糖，聚乙烯吡咯烷酮，聚乙二醇，明胶等水溶性高分子物质的溶液通过过滤器来处理孔径为0.025〜0.05μm的膜过滤器。 使用如此处理的过滤器，以高回收率的HGH活性过滤人生长激素（HGH）的溶液以除去可能存在于HGH制剂中的Creutzfeldt-Jacob病病原体。

公开(公告)号：EP0219295B1

公开(公告)日：1994-01-19

申请号：EP86307707.9

申请日：1986-10-06

申请人： NIHON CHEMICAL RESEARCH KABUSHIKI KAISHA also known as JCR PHARMACEUTICALS CO., LTD

发明人： Hiratani, Hajime ,  Tateishi, Jun ,  Kitamoto, Tetsuyuki

IPC分类号： C07K3/26

CPC分类号： C07K14/615 ,  A61K38/00 ,  A61K38/27 ,  A61L2/0017 ,  A61L2/022

摘要： A membrane filter of 0.025 to 0.05 mu m pore size is previously treated by passing a solution of a water-soluble high molecular substance such as albumin, dextran,polyvinylpyrrolidone, polyethyleneglycol, gelatin or the like through the filter. Employing the filter thus treated, a solution of human growth hormone (HGH) is filtered at high recovery rate of HGH activity to remove Creutzfeldt-Jacob disease pathogen which may exist in HGH preparations.

公开(公告)号：EP0219295A3

公开(公告)日：1989-03-22

申请号：EP86307707.9

申请日：1986-10-06

申请人： NIHON CHEMICAL RESEARCH KABUSHIKI KAISHA also known as JCR PHARMACEUTICALS CO., LTD

发明人： Hiratani, Hajime ,  Tateishi, Jun ,  Kitamoto, Tetsuyuki

IPC分类号： C07K3/26

CPC分类号： C07K14/615 ,  A61K38/00 ,  A61K38/27 ,  A61L2/0017 ,  A61L2/022

摘要： A membrane filter of 0.025 to 0.05 µm pore size is previously treated by passing a solution of a water-soluble high molecular substance such as albumin, dextran,polyvinylpyrrolidone, poly­ethyleneglycol, gelatin or the like through the filter. Employ­ing the filter thus treated, a solution of human growth hormone (HGH) is filtered at high recovery rate of HGH activity to remove Creutzfeldt-Jacob disease pathogen which may exist in HGH pre­parations.